Compare SNDR & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDR | ICUI |
|---|---|---|
| Founded | 1935 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 3.9B |
| IPO Year | 2016 | 1995 |
| Metric | SNDR | ICUI |
|---|---|---|
| Price | $26.11 | $133.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 5 |
| Target Price | $27.77 | ★ $182.25 |
| AVG Volume (30 Days) | ★ 729.1K | 263.1K |
| Earning Date | 04-29-2026 | 05-22-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | ★ 0.59 | 0.03 |
| Revenue | ★ $5,674,300,000.00 | $2,231,262,000.00 |
| Revenue This Year | $5.14 | N/A |
| Revenue Next Year | $6.49 | $4.46 |
| P/E Ratio | ★ $43.49 | $4,406.67 |
| Revenue Growth | ★ 7.25 | N/A |
| 52 Week Low | $20.11 | $107.02 |
| 52 Week High | $30.98 | $160.29 |
| Indicator | SNDR | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 36.44 | 32.88 |
| Support Level | $24.02 | $125.04 |
| Resistance Level | $27.09 | $136.39 |
| Average True Range (ATR) | 1.07 | 6.29 |
| MACD | -0.30 | -2.10 |
| Stochastic Oscillator | 26.52 | 17.68 |
Schneider National Inc is a provider of surface transportation and logistics solutions in North America. The Company offers truckload, intermodal, and logistics services to a diverse customer base throughout the continental United States, Canada, and Mexico. The company's segments include Truckload; Intermodal; Logistics and other. It generates maximum revenue from the Truckload segment.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.